Literature DB >> 31257301

One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.

Yoshimitsu Soga1, Masahiko Fujihara2, Yusuke Tomoi1, Osamu Iida3, Takayuki Ishihara3, Daizo Kawasaki4, Kenji Ando1.   

Abstract

AIM: Paclitaxel-eluting stents' (Eluvia and Zilver PTX) effectiveness has been recently reported for femoropopliteeal (FP) lesions. However, there is no evaluation of one-year late lumen loss (LLL). Therefore, we evaluated one-year LLL after implantation with Eluvia or Zilver PTX.
METHODS: This was a multicenter, prospective study. Patients who had symptomatic de novo lesions in the native FP artery were enrolled. The primary endpoint was one-year angiographic LLL, and the secondary endpoints were binary restenosis and target lesion revascularization (TLR) at one year.
RESULTS: From December 2015 to December 2016, 48 patients (Eluvia, 36 patients; Zilver PTX, 12 patients) were enrolled. No significant difference was found in baseline and lesion characteristics between both groups. One-year, LLL was significantly lower in the Eluvia group (0.60 {plus minus}0.80 mm) than in the Zilver PTX group (1.74 {plus minus}0.89 mm) (P=0.0003). Negative LLL was observed only in the Eluvia group (0% vs. 23%, p=0.096). The binary restenosis rate was significantly lower than in the Zilver PTX group (0% vs. 16.7%, P=0.012). The one-year TLR in the Eluvia group tended to be lower (0% vs. 8.3%, P=0.08). Stent thrombosis was not observed in either group.
CONCLUSION: One-year LLL in the Eluvia group was significantly lower than that in the Zilver PTX group for FP lesions.

Entities:  

Keywords:  Drug-eluting stent; Endovascular therapy; Femoropopliteal disease

Year:  2019        PMID: 31257301      PMCID: PMC7049471          DOI: 10.5551/jat.50369

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  16 in total

1.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

2.  Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials.

Authors:  Christos Kasapis; Peter K Henke; Stanley J Chetcuti; Gerald C Koenig; John E Rectenwald; Venkataramu N Krishnamurthy; Paul Michael Grossman; Hitinder S Gurm
Journal:  Eur Heart J       Date:  2008-11-21       Impact factor: 29.983

3.  1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.

Authors:  Theodosios Bisdas; Efthymios Beropoulis; Angeliki Argyriou; Giovanni Torsello; Konstantinos Stavroulakis
Journal:  JACC Cardiovasc Interv       Date:  2018-05-28       Impact factor: 11.195

4.  Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up.

Authors:  Stefan Müller-Hülsbeck; Koen Keirse; Thomas Zeller; Herman Schroë; Juan Diaz-Cartelle
Journal:  Cardiovasc Intervent Radiol       Date:  2017-09-25       Impact factor: 2.740

5.  Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses.

Authors:  Osamu Iida; Masaaki Uematsu; Yoshimitsu Soga; Keisuke Hirano; Kenji Suzuki; Hiroyoshi Yokoi; Toshiya Muramatsu; Naoto Inoue; Shinsuke Nanto; Seiki Nagata
Journal:  Catheter Cardiovasc Interv       Date:  2011-07-29       Impact factor: 2.692

6.  Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery.

Authors:  Martin Schillinger; Schila Sabeti; Christian Loewe; Petra Dick; Jasmin Amighi; Wolfgang Mlekusch; Oliver Schlager; Manfred Cejna; Johannes Lammer; Erich Minar
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

7.  Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST).

Authors:  Hans Krankenberg; Michael Schlüter; Hermann J Steinkamp; Karlheinz Bürgelin; Dierk Scheinert; Karl-Ludwig Schulte; Erich Minar; Patrick Peeters; Marc Bosiers; Gunnar Tepe; Bernhard Reimers; Felix Mahler; Thilo Tübler; Thomas Zeller
Journal:  Circulation       Date:  2007-06-25       Impact factor: 29.690

8.  Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study.

Authors:  Marc Bosiers; Giovanni Torsello; Hans-Martin Gissler; Johannes Ruef; Stefan Müller-Hülsbeck; Thomas Jahnke; Patrick Peeters; Kim Daenens; Johannes Lammer; Herman Schroë; Klaus Mathias; Renate Koppensteiner; Frank Vermassen; Dierk Scheinert
Journal:  J Endovasc Ther       Date:  2009-06       Impact factor: 3.487

9.  Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial.

Authors:  Yao-Jun Zhang; Christos V Bourantas; Takashi Muramatsu; Javaid Iqbal; Vasim Farooq; Roberto Diletti; Carlos A M Campos; Yoshinobu Onuma; Hector M Garcia-Garcia; Patrick W Serruys
Journal:  EuroIntervention       Date:  2014-10       Impact factor: 6.534

Review 10.  Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications.

Authors:  Krishna J Rocha-Singh; Thomas Zeller; Michael R Jaff
Journal:  Catheter Cardiovasc Interv       Date:  2014-02-10       Impact factor: 2.692

View more
  2 in total

1.  Impact of Peak Systolic Velocity Ratio after Drug-Coated Balloon for Femoropopliteal Disease: Three-Month Serial Observation Vessel Echo Study.

Authors:  Daizo Kawasaki; Aya Nakata; Kunihiko Nishian; Machiko Nishimura; Reiko Fujiwara; Tsuyoshi Nakata; Masashi Fukunaga
Journal:  J Atheroscler Thromb       Date:  2021-09-29       Impact factor: 4.394

2.  Clinical performance of polymer-coated paclitaxel-eluting stent implanted for diffuse and calcified superficial femoral artery stenotic lesions: Insights from a patient on hemodialysis.

Authors:  Naoki Yoshioka; Kensuke Takagi; Takahiro Tokuda; Yasuhiro Morita; Itsuro Morishima
Journal:  SAGE Open Med Case Rep       Date:  2021-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.